| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Genmab A/S (CO: GMAB)
GMAB Technical Analysis
5
| As on 2nd Oct 2025 GMAB STOCK Price closed @ 2025.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1692.08 & Strong Buy for SHORT-TERM with Stoploss of 1915.55 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GMABSTOCK Price
| Open | 2000.00 | Change | Price | % |
| High | 2047.00 | 1 Day | 38.50 | 1.94 |
| Low | 1993.50 | 1 Week | 200.00 | 10.96 |
| Close | 2025.00 | 1 Month | 451.00 | 28.65 |
| Volume | 182722 | 1 Year | 18.00 | 0.90 |
| 52 Week High 2065.00 | 52 Week Low 1168.50 | ||||
CO Denmark Most Active Stocks
| SAS | 0.01 | 0.00% |
| NOVO-B | 371.15 | 1.25% |
| CONFRZ | 0.02 | 0.00% |
| ORSTED | 117.00 | 0.00% |
| VWS | 127.40 | -0.43% |
| ALMB | 17.11 | -3.88% |
| BIF | 0.32 | -3.03% |
| AMBU-B | 103.40 | 2.17% |
| DANSKE | 265.40 | -3.28% |
| GREENH | 0.41 | -6.82% |
CO Denmark Top Gainers Stocks
CO Denmark Top Losers Stocks
| GMAB Daily Charts |
GMAB Intraday Charts |
Whats New @ Bazaartrend |
GMAB Free Analysis |
|
|
GMAB Important Levels Intraday
| RESISTANCE | 2128.09 |
| RESISTANCE | 2095.03 |
| RESISTANCE | 2074.59 |
| RESISTANCE | 2054.16 |
| SUPPORT | 1995.84 |
| SUPPORT | 1975.41 |
| SUPPORT | 1954.97 |
| SUPPORT | 1921.91 |
GMAB Forecast October 2025
| 4th UP Forecast | 2375.71 |
| 3rd UP Forecast | 2263.24 |
| 2nd UP Forecast | 2193.71 |
| 1st UP Forecast | 2124.19 |
| 1st DOWN Forecast | 1925.81 |
| 2nd DOWN Forecast | 1856.29 |
| 3rd DOWN Forecast | 1786.76 |
| 4th DOWN Forecast | 1674.29 |
GMAB Weekly Forecast
| 4th UP Forecast | 2291.89 |
| 3rd UP Forecast | 2206.30 |
| 2nd UP Forecast | 2153.39 |
| 1st UP Forecast | 2100.48 |
| 1st DOWN Forecast | 1949.52 |
| 2nd DOWN Forecast | 1896.61 |
| 3rd DOWN Forecast | 1843.70 |
| 4th DOWN Forecast | 1758.11 |
GMAB Forecast2025
| 4th UP Forecast | 3819.04 |
| 3rd UP Forecast | 3243.68 |
| 2nd UP Forecast | 2888.04 |
| 1st UP Forecast | 2532.4 |
| 1st DOWN Forecast | 1517.61 |
| 2nd DOWN Forecast | 1161.96 |
| 3rd DOWN Forecast | 806.32 |
| 4th DOWN Forecast | 230.96 |
Genmab A/S ( CO Denmark Symbol : GMAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GMAB Business Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Address: Kalvebod Brygge 43, Copenhagen, Denmark, 1560
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service